Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Preimplantation Genetic Testing Market, By PGD/PGS
7.1. Preimplantation Genetic Testing Market, By PGD/PGS, 2021-2028
7.1.1. Preimplantation Genetic Diagnosis (PGD)
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Preimplantation Genetic Screening (PGS)
7.1.2.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Preimplantation Genetic Testing Market, By Application
8.1. Preimplantation Genetic Testing Market, by Application, 2021-2028
8.1.1. Embryo HLA Typing for Stem Cell Therapy
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. IVF Prognosis
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Late Onset Genetic Disorders
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Inherited Genetic Disease
8.1.4.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Preimplantation Genetic Testing Market, By Type
9.1. Preimplantation Genetic Testing Market, By Type, 2021-2028
9.1.1. Chromosomal Abnormalities
9.1.1.1. Market Revenue and Forecast (2016-2028)
9.1.2. X-linked Diseases
9.1.2.1. Market Revenue and Forecast (2016-2028)
9.1.3. Embryo Testing
9.1.3.1. Market Revenue and Forecast (2016-2028)
9.1.4. Aneuploidy Screening
9.1.4.1. Market Revenue and Forecast (2016-2028)
9.1.5. HLA Typing
9.1.5.1. Market Revenue and Forecast (2016-2028)
9.1.6. Other PGT Types
9.1.6.1. Market Revenue and Forecast (2016-2028)
Chapter 10. Global Preimplantation Genetic Testing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.1.2. Market Revenue and Forecast, by Application (2016-2028)
10.1.3. Market Revenue and Forecast, By Type (2016-2028)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2028)
10.1.4.3. Market Revenue and Forecast, By Type (2016-2028)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2028)
10.1.5.3. Market Revenue and Forecast, By Type (2016-2028)
10.2. Europe
10.2.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.2.2. Market Revenue and Forecast, by Application (2016-2028)
10.2.3. Market Revenue and Forecast, By Type (2016-2028)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2028)
10.2.4.3. Market Revenue and Forecast, By Type (2016-2028)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2028)
10.2.5.3. Market Revenue and Forecast, By Type (2016-2028)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2028)
10.2.6.3. Market Revenue and Forecast, By Type (2016-2028)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2028)
10.2.7.3. Market Revenue and Forecast, By Type (2016-2028)
10.3. APAC
10.3.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.3.2. Market Revenue and Forecast, by Application (2016-2028)
10.3.3. Market Revenue and Forecast, By Type (2016-2028)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2028)
10.3.4.3. Market Revenue and Forecast, By Type (2016-2028)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2028)
10.3.5.3. Market Revenue and Forecast, By Type (2016-2028)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2028)
10.3.6.3. Market Revenue and Forecast, By Type (2016-2028)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2028)
10.3.7.3. Market Revenue and Forecast, By Type (2016-2028)
10.4. MEA
10.4.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.4.2. Market Revenue and Forecast, by Application (2016-2028)
10.4.3. Market Revenue and Forecast, By Type (2016-2028)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2028)
10.4.4.3. Market Revenue and Forecast, By Type (2016-2028)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2028)
10.4.5.3. Market Revenue and Forecast, By Type (2016-2028)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2028)
10.4.6.3. Market Revenue and Forecast, By Type (2016-2028)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2028)
10.4.7.3. Market Revenue and Forecast, By Type (2016-2028)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.5.2. Market Revenue and Forecast, by Application (2016-2028)
10.5.3. Market Revenue and Forecast, By Type (2016-2028)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2028)
10.5.4.3. Market Revenue and Forecast, By Type (2016-2028)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By PGD/PGS (2016-2028)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2028)
10.5.5.3. Market Revenue and Forecast, By Type (2016-2028)
Chapter 11. Company Profiles
11.1. Illumina Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Thermo Fisher Scientific, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Natera, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bioarray S.L.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Good Start Genetics, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Laboratory Corporation of America Holdings
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. California Pacific Medical Center
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Quest Diagnostics Incorporated
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Reproductive Health Science Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. CooperSurgical, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Genea Limited
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. IGENOMIX
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Reproductive Genetic Innovations, LLC.
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. F. Hoffmann-La Roche AG.
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. CombiMatrix.
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms